2014 Issue No. 12 - Week 23 (as of 9 Jun 2014) HIGHLIGHTS Polio Update in Lao PDR Lao People’s Democratic Republic was classified as a “tier 2” risk country due to persistent polio immunity gaps which leave the country vulnerable to poliovirus importations. At the 22nd EPI TAG Meeting, all tier 2 countries were requested to complete a draft polio endgame plan completed by mid-2014. Lao PDR is the first tier 2 country in the Region to comply with this request. To ensure high-level support for the implementation of the polio endgame in Lao PDR, in March 2014, an advocacy event was conducted. Representatives from the Lao PDR National Immunization Program, WPRO, and other partner organizations met with the Vice Minister of Health to brief her on the activities called for by the Polio Endgame. Following the meeting, a timeline with key activities pertaining to the polio endgame was proposed by the National Immunization Program and was validated by the Vice Minister. Following this meeting, in April 2014, Lao PDR submitted its application to the GAVI to support the introduction of the inactivated poliovirus vaccine (IPV) in October 2015. Additionally, in early June, the National Immunization Program (NIP) and National Center for Laboratory and Epidemiology (NCLE),with support from partners, developed a comprehensive Polio Endgame Plan for Lao PDR for 2014-2018. This plan outlines the key areas of emphasis and actions to be taken relevant to the polio program including: (1) surveillance, (2) boosting population immunity, introducing IPV, and switching from tOPV to bOPV, (3) containment and certification, and (4) the polio legacy. Special congratulations to the NIP and NCLE for their hard work to ensure the timely initiation of the Polio Endgame and continued efforts to protect the children of Lao PDR by keeping polio-free.
Polio Bulletin 90% 80% 70% 60%
Chart 1. Non-polio AFP rate and adequate specimen collection rate, 2012–2014* 3.0 2.5 100%
Chart 2. Percent cases with pending classification > 90 days after onset, 2014 CHN Cases with adequate specimens (%)
17.0% 25.0% 0.0% 10.3% 15.9% 50.0% 14.3% 0% 10% 20% 30% 40% 50% 60%
KHM LAO MYS PHL PNG VNM
Non-polio AFP rate
2.0 1.5 1.0 0.5 0.0 12 13 14 CHN 12 13 14 KHM 12 13 14 LAO 12 13 14 MYS 12 13 14 PHL 12 13 14 PNG 12 13 14 VNM
50% 40% 30% 20% 10% 0%
* AFP rate annualized as of week 23
Chart 3. Polio immunization status of reported AFP cases, 2014 100% 100%
Chart 4. Percentage of samples received at the lab ≤ 3 days of collection, 2014
80%
80%
60%
60%
53%
58% 42%
40%
40% 28%
20% 20%
0% CHN KHM ≥ 3 doses
LAO
MYS
PHL 0 doses
PNG Unknown
VNM
0% CHN
0% KHM
0% LAO MYS PHL
0% PNG VNM
1-2 doses
CONTACT US Expanded Programme on Immunization Regional Office for the Western Pacific World Health Organization P.O. Box 2932, 1000 Manila, Philippines Phone: +63 2 5288001 Fax: +63 2 5211036, 5260279 Email: WPR_EPIdata@wpro.who.int Web: www.wpro.who.int/immunization
Note: Priority countries were selected for the charts. Official WHO acronyms have been used for abbreviation: CHN (China), KHM (Cambodia), LAO (Lao People’s Democratic Republic), MYS (Malaysia), PHL (Philippines), PNG (Papua New Guinea), and VNM (Viet Nam).
Table 1A. Classification of AFP cases with onset in 2013 and key surveillance indicators 2012 Classification Total reported cases Annual expected cases <15 years of age Pending Total reported cases Confirmed wild poliovirus Vaccinederived poliovirus (VDPV) Non-polio AFP rate % % with % with % with any investigated 60-day adequate 3 2 days of ≤ specimen 5 specimens 2 4 follow-up notification ≥ 80% ≥ 80% ≥ 80% Latest report date 6 Days since last report 7
2013 Indicators
Poliocompatible
Discarded (Non-polio)
Total
> 90 days 1 # (%)
≥1
Australia Brunei Darussalam Cambodia China Hong Kong (China) Japan Lao People's Democratic Republic Macao (China) Malaysia Mongolia New Zealand Papua New Guinea Philippines Republic of Korea Singapore Viet Nam Pacific island countries Total 1. 2. 3. 4. 5. 6. 7.
56 1 107 6173 14 0 55 0 141 9 8 10 403 95 10 514 4 7600
43 1 45 2225 8 167 25 1 77 7 9 30 378 76 6 241 10 3349
62 1 73 5623 12 0 48 1 155 7 12 18 277 84 7 459 8 6847
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
1 0 0 1 0 0 0 0 0 0 0 2 0 0 0 0 4
61 1 73 5622 12 48 1 155 7 12 18 275 84 7 459 7 6842
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1
0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (12.5%) 1 (0.0%) Green Yellow Red
1.44 1.00 1.62 2.53 1.50 1.92 1.00 2.01 1.00 1.33 0.60 0.73 1.11 1.17 1.90 0.80 2.04
39% 100% 81% 93% 100% 58% 100% 83% 86% 50% 28% 68% 93% 71% 97% 63% 91%
71% 100% 96% 99% 100% 90% 100% 100% 100% 83% 83% 96% 100% 100% 99% 100% 99%
100% 100% 78% 100% 100% 98% 100% 85% 100% 83% 83% 98% 94% 86% 92% 100% 98%
0% 100% 98% 100% 100% 100% 100% 100% 50% 100% 100% 100% 67% 86%
08-Apr-14 06-Feb-14 13-Mar-14 28-May-14 06-Feb-14 26-May-14 14-Jan-14 31-Mar-14 07-Mar-14 27-Feb-14 26-Feb-14 08-Apr-14 20-Mar-14 08-Jan-14 17-Apr-14 14-May-14
26
Number (%) of reported cases pending classification more than 90 days from date of onset of paralysis to date of last report Percentage of reported cases with two stool specimens collected 24 hours apart and within 14 days of onset of paralysis Percentage of reported cases with at least one specimen Percentage of reported cases investigated within two days of notification Percentage of reported cases with inadequate specimens followed-up within 60 days of onset of paralysis Report date is fixed as soon as all cases for the year have been classified Countries are expected to submit data at least once per month to WPRO
Reached or surpassed target Nearly reached target: 0.5–0.99 for non-polio AFP rate; 60–79% for other indicators Substantially below target
2
Polio Bulletin
Table 1B. Classification of AFP cases with onset in 2014 and key surveillance indicators 2013 Classification Total reported cases Annual expected cases <15 years of age Pending Total reported cases Confirmed wild poliovirus Vaccinederived poliovirus (VDPV) Non-polio AFP rate 2 % % with % with % with any investigated adequate 60-day 4 2 days of ≤ specimen 6 specimens 3 5 follow-up notification ≥ 80% ≥ 80% ≥ 80% Latest report date Days since last report 7
2014 Indicators
Poliocompatible
Discarded (Non-polio)
Total
> 90 days 1 # (%)
≥1
Australia Brunei Darussalam Cambodia China Hong Kong (China) Japan Lao People's Democratic Republic Macao (China) Malaysia Mongolia New Zealand Papua New Guinea Philippines Republic of Korea Singapore Viet Nam Pacific island countries Total 1. 2. 3. 4. 5. 6. 7.
62 1 73 5623 12 0 48 1 155 7 12 18 277 84 7 459 8 6847
44 1 45 2225 8 167 25 1 77 8 9 30 378 76 6 241 10 3351
19 0 8 1793 8 0 11 0 58 3 2 6 88 31 4 77 3 2111
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
7 0 653 7 5 36 1 0 0 19 29 4 13 0 774
12 8 1140 1 6 22 2 2 6 69 2 0 64 3 1337
2 (10.5%) 2 (25.0%) 305 (17.0%) 1 (12.5%) 0 (0.0%) 6 (10.3%) 0 (0.0%) 1 (50.0%) 3 (50.0%) 14 (15.9%) 0 (0.0%) 0 (0.0%) 11 (14.3%) 2 (66.7%) 347 (16.4%) Green Yellow Red
0.98 0.40 1.82 2.26 0.99 1.70 0.85 0.50 0.45 0.53 0.92 1.51 0.72 0.68 1.42
32% 88% 92% 88% 55% 72% 100% 50% 0% 64% 77% 75% 97% 67% 89%
58% 100% 98% 100% 100% 100% 100% 100% 100% 93% 100% 100% 100% 100% 98%
84% 100% 100% 100% 91% 57% 100% 100% 50% 95% 94% 100% 88% 100% 98%
0% 0% 71% 100% 0% 25% 0% 0% 3% 86% 100% 0% 0% 51%
23-May-14 06-Feb-14 02-May-14 04-Jun-14 03-Jun-14 06-May-14 20-May-14 22-May-14 09-Jun-14 16-May-14 07-May-14 12-May-14 16-May-14 03-Jun-14 26-May-14 14-May-14
17 123 38 5 6 34 20 18 0 24 33 28 24 6 14 26
Number (%) of reported cases pending classification more than 90 days from date of onset of paralysis to date of last report Annualized non-polio AFP rate per 100 000 population under 15 years of age Percentage of reported cases with two stool specimens collected 24 hours apart and within 14 days of onset of paralysis Percentage of reported cases with at least one specimen Percentage of reported cases investigated within two days of notification Percentage of reported cases with inadequate specimens followed-up within 60 days of onset of paralysis Countries are expected to submit data at least once per month to WPRO
Reached or surpassed target Nearly reached target: 0.5–0.99 for non-polio AFP rate; 60–79% for other indicators Substantially below target
3
Polio Bulletin
Table 2A. Laboratory investigation of AFP cases with onset in 2013 and key laboratory indicators Virus isolation results Country National polio laboratory Total no. of AFP L20B cases with specimens positive L20B positive + NPEV NPEV only Pending ≤ 14 Negative days Intratypic % % results differentiation Latest Pending reported specimens / Sequencing positive report date > 14 2 ≤ 14 days for NPEV lab 1 days ≥ 80% No. of isolates referred Type 1 W ild Sabin VDPV Wild Type 2 Sabin Intratypic differentiation (ITD) results Type 3 VDPV Wild Sabin VDPV NPEV 3
1
Pending ITD
% ITD results Discordant reported ≤ 7 days of pending receipt sequencing ≥ 80%
Australia Brunei Darussalam Papua New Guinea Pacific island countries Japan Cambodia Lao People's Democratic Republic Malaysia Mongolia New Zealand Philippines Republic of Korea Singapore Viet Nam, North Viet Nam, South China China, Anhui China, Beijing China, Fujian China, Gansu China, Guangdong China, Guangxi China, Hebei China, Heilongjiang China, Henan China, Hunan China, Jiangsu China, Jiangxi China, Jilin China, Shaanxi China, Shandong China, Shanghai China, Shanxi China, Sichuan China, Tianjin China, Xinjiang China, Yunnan China, Zhejiang China, Chongqing China, Guizhou China, Hainan China, Hubei China, Liaoning China, Neimongol China, Ningxia China, Qinghai China, Tibet Hong Kong (China) Macao (China) Total
VIDRL VIDRL VIDRL VIDRL NIID NIID NIID IMR PHI IESR RITM NIH SGH NIHE PI CCDC Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab PHLC PHLC
44 1 18 8 0 70 43 156 7 9 366 83 7 229 225 5570 268 31 161 112 377 248 387 128 576 297 289 190 64 110 389 28 212 357 23 86 255 163 82 232 41 230 109 80 19 16 10 12 0 6848
0 0 0 0 1 0 0 0 0 0 0 1 2 2 100 4 1 4 4 2 4 12 3 13 2 9 2 0 1 17 2 3 0 1 5 2 3 0 0 0 3 0 3 0 0 0 0 106
0 0 0 0 0 0 0 0 0 1 0 0 0 0 3 0 0 0 0 0 0 2 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 4
9 0 3 4 21 10 7 1 2 40 2 0 41 21 582 35 0 16 6 37 28 62 7 103 41 7 14 3 2 32 0 9 39 1 6 30 19 8 23 5 31 14 3 0 1 0 0 743
35 1 15 4 48 33 149 6 7 325 81 6 186 208 4885 229 30 141 102 338 216 311 118 460 254 273 174 61 107 340 26 200 318 21 75 222 141 74 209 36 196 95 74 19 15 10 12 6001
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
100% 100% 100% 100% 94% 97% 98% 100% 94% 95% 100% 100% 95% 98% 60% 52% 77% 80% 73% 60% 20% 64% 79% 55% 90% 43% 70% 61% 91% 69% 98% 42% 32% 87% 81% 74% 37% 78% 74% 71% 40% 72% 67% 55% 63% 20% 97% 65%
20% 0% 16% 44% 24% 21% 3% 14% 22% 9% 3% 0% 15% 9% 9% 11% 0% 7% 5% 8% 9% 13% 5% 14% 13% 2% 7% 5% 2% 6% 0% 4% 10% 4% 6% 10% 9% 9% 9% 11% 13% 11% 4% 0% 3% 0% 0% 9%
29-Jan-14 29-Jan-14 29-Jan-14 29-Jan-14 12-Feb-14 02-Apr-14 25-Feb-14 11-Feb-14 17-Mar-14 08-May-14 18-Feb-14 15-Jan-14 11-Feb-14 18-Mar-14 14-May-14
VIDRL VIDRL VIDRL VIDRL NIID NIID NIID IMR NIID IESR VIDRL NIID SGH NIID NIID Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab CCDC CCDC CCDC CCDC CCDC CCDC CCDC CCDC CCDC
0 0 0 0 0 2 0 0 0 0 3 0 2 4 4 261 12 15 8 12 10 13 18 4 27 4 11 31 0 0 31 10 6 0 2 12 5 7 0 2 1 6 7 3 4 0 0 0 0 276
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 1 0 0 2 71 3 6 2 1 4 3 9 1 6 0 9 0 9 4 2 0 2 1 1 0 0 3 3 0 2 74
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
2 1 2 2 0 95 4 6 3 6 4 4 3 0 14 2 1 11 11 6 2 2 7 0 2 2 0 1 2 0 2 102
0 0 0 0 0 4 0 0 0 0 0 0 0 0 0 0 0 4 0 0 0 0 0 0 0 0 0 0 0 0 0 4
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 1 0 2 2 77 5 3 3 5 2 6 6 3 7 2 1 2 11 0 2 0 3 4 4 0 1 2 2 3 0 82
0 0 0 0 0 14 0 0 0 0 0 0 0 0 0 0 0 14 0 0 0 0 0 0 0 0 0 0 0 0 0 14
0 0 0 0 0 3 0 0 0 0 0 0 0 0 0 0 0 0 0 0 2 0 0 0 1 0 0 0 0 0 0 3
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100%
16-Jan-14 16-Jan-14
PHLC PHLC
1. IESR (Institute of Environmental Science and Research, New Zealand); IMR (Institute of Medical Research, Malaysia); NIH (National Institute of Health, Republic of Korea); NIHE (National Institute of Hygiene and Epidemiology, Ha Noi, Viet Nam); NIID (National Institute of Infectious Diseases, Japan); PHI (Public Health Institute, Mongolia); PHLC (Public Health Laboratory Center, Hong Kong); PI (Pasteur Institute, Ho Chi Minh, Viet Nam); RITM (Research Institute for Tropical Medicine, Philippines); SGH (Singapore General Hospital); VIDRL (Victorian Infectious Diseases Reference Laboratory, Australia) 2. The target of 14 days for the timeliness of virus isolation will be used for all polio laboratories 3. NPEV growing in L20B cells 4. Twenty-two provincial laboratories in China perform ITD from 2013
4
Polio Bulletin
Table 2B. Laboratory investigation of AFP cases with onset in 2014 and key laboratory indicators Virus isolation results Country National polio laboratory Total no. of AFP L20B cases with specimens positive L20B positive + NPEV NPEV only Pending Negative ≤ 14 days Intratypic % % results differentiation Latest Pending reported specimens / Sequencing report date positive > 14 2 ≤ 14 days for NPEV lab 1 days ≥ 80% No. of isolates referred Type 1 W ild Sabin VDPV Wild Type 2 Sabin Intratypic differentiation (ITD) results Type 3 VDPV Wild Sabin VDPV NPEV 3
1
Pending ITD
% ITD results Discordant reported ≤ 7 days of pending receipt sequencing ≥ 80%
Australia Brunei Darussalam Papua New Guinea Pacific island countries Japan Cambodia Lao People's Democratic Republic Malaysia Mongolia New Zealand Philippines Republic of Korea Singapore Viet Nam, North Viet Nam, South China China, Anhui China, Beijing China, Fujian China, Gansu China, Guangdong China, Guangxi China, Hebei China, Heilongjiang China, Henan China, Hunan China, Jiangsu China, Jiangxi China, Jilin China, Shaanxi China, Shandong China, Shanghai China, Shanxi China, Sichuan China, Tianjin China, Xinjiang China, Yunnan China, Zhejiang China, Chongqing China, Guizhou China, Hainan China, Hubei China, Liaoning China, Neimongol China, Ningxia China, Qinghai China, Tibet Hong Kong (China) Macao (China) Total
VIDRL VIDRL VIDRL VIDRL NIID NIID NIID IMR PHI IESR RITM NIH SGH NIHE PI CCDC Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab PHLC PHLC
4 0 0 2 0 9 13 62 3 2 123 31 4 45 44 1766 75 7 74 46 105 73 93 49 171 70 90 58 19 19 146 14 84 116 9 29 89 60 31 73 8 59 46 33 15 4 1 7 0 2115
0 0 3 0 0 0 0 1 0 0 0 0 28 1 0 0 1 1 0 0 0 1 1 4 0 0 0 1 2 2 1 0 1 11 0 0 1 0 0 0 0 0 0 0 0 32
0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1
0 0 1 3 2 0 1 4 0 0 7 6 108 0 0 6 0 11 13 5 0 12 7 1 3 0 1 5 0 0 12 2 0 9 4 3 5 2 7 0 0 0 0 0 0 132
4 1 5 10 50 2 1 106 29 4 38 36 1578 73 7 66 45 93 60 86 45 156 60 80 50 19 18 132 12 82 102 7 25 69 56 26 62 6 49 41 31 15 4 1 7 1871
0 1 0 0 10 1 0 0 2 0 0 2 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 17
0 0 0 0 0 0 0 13 0 0 0 0 50 1 0 2 0 0 0 1 4 2 2 5 5 0 0 7 0 0 1 0 3 0 0 2 5 0 3 5 2 0 0 0 0 63
88% 100% 100% 100% 100% 100% 100% 90% 93% 100% 100% 90% 61% 50% 86% 91% 71% 73% 5% 53% 82% 73% 81% 29% 87% 82% 66% 64% 96% 39% 25% 89% 96% 50% 48% 81% 82% 63% 53% 88% 84% 70% 100% 0% 95% 64%
0% 0% 6% 19% 4% 0% 50% 3% 0% 0% 14% 13% 5% 0% 0% 7% 0% 7% 16% 4% 0% 5% 10% 1% 5% 0% 5% 3% 0% 0% 9% 17% 0% 8% 6% 7% 7% 25% 13% 0% 0% 0% 0% 0% 0% 5%
14-Mar-14 14-Mar-14 14-Mar-14 14-Mar-14 27-May-14 09-Jun-14 14-May-14 05-Jun-14 03-Jun-14 30-May-14 16-May-14 30-May-14 30-May-14 03-Jun-14 04-Jun-14
VIDRL VIDRL VIDRL VIDRL NIID NIID NIID IMR NIID IESR VIDRL NIID SGH NIID NIID Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab CCDC CCDC CCDC CCDC CCDC CCDC CCDC CCDC CCDC
0 0 0 0 0 4 0 0 0 0 0 0 0 0 0 84 0 5 0 6 4 0 2 0 2 0 12 0 0 0 4 2 8 3 0 4 24 0 2 4 0 0 2 0 0 0 0 0 0 88
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 25 2 2 2 2 0 4 2 0 0 2 2 7 0 0 0 25
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
4 26 0 2 2 0 0 4 0 0 4 1 2 7 2 2 0 30
0 2 0 0 0 0 0 0 0 0 2 0 0 0 0 0 0 2
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 31 3 2 0 0 2 4 2 2 2 0 0 10 0 2 2 31
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100%
28-May-14 28-May-14
PHLC PHLC
1. IESR (Institute of Environmental Science and Research, New Zealand); IMR (Institute of Medical Research, Malaysia); NIH (National Institute of Health, Republic of Korea); NIHE (National Institute of Hygiene and Epidemiology, Ha Noi, Viet Nam); NIID (National Institute of Infectious Diseases, Japan); PHI (Public Health Institute, Mongolia); PHLC (Public Health Laboratory Center, Hong Kong); PI (Pasteur Institute, Ho Chi Minh, Viet Nam); RITM (Research Institute for Tropical Medicine, Philippines); SGH (Singapore General Hospital); VIDRL (Victorian Infectious Diseases Reference Laboratory, Australia) 2. The target of 14 days for the timeliness of virus isolation will be used for all polio laboratories 3. NPEV growing in L20B cells 4. Twenty-two provincial laboratories in China perform ITD from 2013
5
Polio Bulletin
Table 3A. Laboratory confirmation of polio isolates from other sources in 2013 Non-AFP cases Country Intratypic Total number Total number differentiation of non-AFP of non-AFP lab 2 cases tested cases with polio isolates for polio Type 1 Wild Sabin VDPV Wild Type 2 Sabin VDPV Wild Type 3 Sabin NPEV Discordant Total number Pending grown pending of samples ITD sequencing processed VDPV in L20B Total number of samples with polio isolates Type 1 Wild Sabin VDPV
1
Environmental samples Type 2 Wild Sabin VDPV Wild Type 3 Sabin NPEV Discordant Pending grown pending ITD sequencing VDPV in L20B
Australia Japan Malaysia Mongolia New Zealand Philippines Republic of Korea Singapore Viet Nam, North Viet Nam, South China (total) China, Anhui China, Beijing China, Fujian China, Gansu China, Guangdong China, Guangxi China, Hebei China, Heilongjiang China, Henan China, Hunan China, Jiangsu China, Jiangxi China, Jilin China, Shaanxi China, Shandong China, Shanghai China, Shanxi China, Sichuan China, Tianjin China, Xinjiang China, Yunnan China, Zhejiang China, Chongqing China, Guizhou China, Hainan China, Hubei China, Liaoning China, Neimongol China, Ningxia China, Qinghai China, Tibet Hong Kong (China) Total
VIDRL NIID IMR PHI IESR VIDRL NIID SGH NIID NIID Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab CCDC CCDC CCDC CCDC CCDC CCDC CCDC CCDC CCDC PHLC
269 0 0 158 0 6 0 0 0 0 28 0 0 0 7 1 0 2 2 0 0 0 2 0 0 2 2 0 2 1 2 0 0 0 0 1 0 0 3 1 0 0 1 462
1 0 6 28 7 1 2 2 2 2 2 2 1 2 1 3 1 1 36
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 5 15 7 0 2 0 0 2 1 1 1 0 0 0 1 1 21
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
1 0 1 11 4 0 0 0 1 1 0 0 0 2 1 1 1 0 13
0 0 0 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 1
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 1 13 4 0 0 2 1 1 1 1 1 0 0 2 0 0 14
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 56 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 56
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0 0 33 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 33
4 4
0 0
1 1
0 0
0 0
2 2
0 0
0 0
1 1
0 0
27 27
0 0
0 0
1. Based on year of collection of sample, if available. Otherwise, based on year of receipt at reference laboratory. 2. CCDC (Chinese Center for Disease Control and Prevention, China); IESR (Institute of Environmental Science and Research, New Zealand); IMR (Institute of Medical Research, Malaysia); NIID (National Institute of Infectious Diseases, Japan); PHI (Public Health Institute, Mongolia); PHLC (Public Health Laboratory Center, Hong Kong); SGH (Singapore General Hospital); VIDRL (Victorian Infectious Diseases Reference Laboratory, Australia)
6
Polio Bulletin
Table 3B. Laboratory confirmation of polio isolates from other sources in 2014 Non-AFP cases Country Intratypic Total number Total number differentiation of non-AFP of non-AFP lab 2 cases tested cases with for polio polio isolates Type 1 Wild Sabin VDPV Wild Type 2 Sabin VDPV Wild Type 3 Sabin NPEV Discordant Total number Pending grown of samples pending ITD processed sequencing VDPV in L20B Total number of samples with polio isolates Type 1 Wild Sabin VDPV
1
Environmental samples Type 2 Wild Sabin VDPV Wild Type 3 Sabin Discordant NPEV Pending pending grown ITD sequencing VDPV in L20B
Australia Japan Malaysia Mongolia New Zealand Philippines Republic of Korea Singapore Viet Nam, North Viet Nam, South China (total) China, Anhui China, Beijing China, Fujian China, Gansu China, Guangdong China, Guangxi China, Hebei China, Heilongjiang China, Henan China, Hunan China, Jiangsu China, Jiangxi China, Jilin China, Shaanxi China, Shandong China, Shanghai China, Shanxi China, Sichuan China, Tianjin China, Xinjiang China, Yunnan China, Zhejiang China, Chongqing China, Guizhou China, Hainan China, Hubei China, Liaoning China, Neimongol China, Ningxia China, Qinghai China, Tibet Hong Kong (China) Total
VIDRL NIID IMR PHI IESR VIDRL NIID SGH NIID NIID Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab Prov. Lab CCDC CCDC CCDC CCDC CCDC CCDC CCDC CCDC CCDC PHLC
10 0 0 70 0 0 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 82
0 0 0 1 1 1
0 0 0 0 0 0
0 0 0 1 1 1
0 0 0 0 0 0
0 0 0 0 0 0
0 0 0 0 0 0
0 0 0 0 0 0
0 0 0 0 0 0
0 0 0 0 0 0
0 0 0 0 0 0
0 6 0 0 0 6
0 0 0 0 0 0
0 0 0 0 0 0
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
0
0
0
0
0
0
0
0
0
0
0
0
0
1. Based on year of collection of sample, if available. Otherwise, based on year of receipt at reference laboratory. 2. CCDC (Chinese Center for Disease Control and Prevention, China); IESR (Institute of Environmental Science and Research, New Zealand); IMR (Institute of Medical Research, Malaysia); NIID (National Institute of Infectious Diseases, Japan); PHI (Public Health Institute, Mongolia); PHLC (Public Health Laboratory Center, Hong Kong); SGH (Singapore General Hospital); VIDRL (Victorian Infectious Diseases Reference Laboratory, Australia)
7
Polio Bulletin
Table 4. Vaccine-derived poliovirus, 2000–2013 Country Cambodia iVDPV1 (1 case) aVDPV1 (1 case) aVDPV3 (1 case) aVDPV3 (1 case)
2000
2001
2002
2003
2004
2005 cVDPV3 (1 case)
2006 cVDPV3 (1 case)
2007
2008
2009
2010
2011
2012
2013
China
aVDPV1 (1 case)
cVDPV1 (2 cases) aVDPV1 (1 case) aVDPV1 (3 cases) ?VDPV1 (4 cases) iVDPV2 (1 case) ?VDPV1 (7 cases) ?VDPV1 (1 case) ?VDPV2 (1 case) VDPV3 (1 case) ?VDPV? (3 cases) ?VDPV? (1 case) aVDPV2 (1 case) ?VDPV? (2 cases) ?VDPV? (1 case) ?VDPV3 (1 case)
aVDPV2 (1 case)
aVDPV1 (1 case) aVDPV1 (1 case) aVDPV2 (3 cases) aVDPV2 (5 cases) aVDPV2 (2 cases) aVDPV2 (1 case) cVDPV2 (2 cases) aVDPV3 (2 cases) cVDPV2 (3 cases) iVDPV2 + iVDPV3 (1 case) iVDPV2 (2 cases) iVDPV2 + iVDPV3 (1 case) iVDPV3 (1 case)
Hong Kong (China) Japan Lao People's Democratic Republic Mongolia Philippines Viet Nam cVDPV1 (3 cases)
aVDPV2 (2 cases)
8
Polio Bulletin